2020 Contracts Licensing Settlement 
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 4, 2021
Yet 2020 saw a slowdown in biosimilar activity with the lowest number of annual biosimilar approvals since 2016 and fewer product launches than 2019—as well as a decrease in district court litigation and post-grant proceedings. Below, we review these notable developments and more from 2020. Biosimilar Approvals and Launches in 2020.
IPilogue
SEPTEMBER 9, 2022
In this contract, it was stipulated that for licences, he would be paid a royalty rate of approximately 50%, but for a sale, such as the sale of a CD, he would be paid a royalty rate of 18%. When Four Tet’s contract was signed in 2001, these standard licensing terms were different for the music industry. Sales vs Licences.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TorrentFreak
AUGUST 21, 2021
A pending settlement agreement included a clause that Tusa couldn’t launch or be involved with any similar services. After the apparent demise of Area 51 but in advance of the settlement being finalized, it’s alleged that Tusa launched a close copy of Area 51 called SingularityMedia, which scooped up Area 51’s customers.
TorrentFreak
JANUARY 11, 2022
Initially, the parties entered settlement discussions. The original complaint lists four copyright registrations but two of these were first published on November 10, 2020, well after the cheats were first made available. The same accusations were also made against Phoenix Digital Group, the alleged creators of the software.
Plagiarism Today
APRIL 7, 2022
Also in 2018, FDN filed the original complaint, targeting both Amazon and CCA, alleging that they both breached contracts and committed copyright infringement. There wasn’t even a system for registering blog content, like this site, until June 2020. But this is where FDN introduces a new wrinkle. Bottom Line.
Fish & Richardson Trademark & Copyright Thoughts
MARCH 8, 2021
This article focuses on regulatory and legislative actions in 2020 that may impact the burgeoning biosimilars space in 2021 and beyond. In particular, the authors review FDA’s preparation for the March 23, 2020 transition date, as well as FDA’s efforts to address biosimilar competition, interchangeability, and the COVID-19 pandemic.
The IPKat
JANUARY 31, 2023
Costs On costs, Oxford University Innovation sought indemnity costs from 12 June 2020. This was because: Both sides engaged in settlement discussions, there was mediation and an Early Neutral Evaluation. The result being that money was due. The Judge commented: " To the contrary, there are good reasons for letting the case rest.
Expert insights. Personalized for you.
52 
Let's personalize your content